Palisade Bio(US:PALI) Globenewswire·2026-02-05 13:45Core Viewpoint - Palisade Bio, Inc. is advancing its clinical-stage biopharmaceutical product, PALI-2108, a once-daily oral PDE4 inhibitor prodrug aimed at treating inflammatory and fibrotic diseases, with a focus on targeted delivery to the terminal ileum and colon [2][6]. Group 1: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs to enhance pharmacology, tolerability, and convenience for patients [6]. - The company is committed to transforming established PDE4 biology into safer oral therapies for chronic inflammatory and fibrotic diseases through its differentiated prodrug platform [6]. Group 2: Product Details - PALI-2108 is designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon, activated by local bacterial bioactivation, which minimizes systemic absorption and improves tolerability [5]. - In a Phase 1b trial, PALI-2108 demonstrated a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events and favorable pharmacokinetics [7]. Group 3: Clinical Development - The company is progressing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, including an extension phase for maintenance of remission [8]. - Early studies are being completed in fibrotic diseases to further assess PALI-2108's safety, pharmacology, and potential therapeutic benefits across inflammatory bowel disease indications [8].